Acknowledgments
We would like to acknowledge the Clinical Research Coordinators team (Li Xuan Tan, Priscilla SH Chong, Angie AQ Yee, Michelle YX Au, Joanna Cheri Hui Ern Peh, Pamela SZ Lum) for their involvement in managing this trial. We also would like to acknowledge the expert panel members for their time given to assessing CURATE.AI applicability.
Funding
National Research Foundation Singapore under its AI Singapore Program Award Number: AISG-GC-2019-002 (DH)
Singapore Ministry of Health's National Medical Research Council (NMRC) under its Open Fund—Large Collaborative Grant (OF-LCG) MOH-OFLCG18May-0028 (DH)
Institute for Digital Medicine (WisDM) Translational Research Program the Yong Loo Lin School of Medicine, National University of Singapore R-719-000-037-733 (DH)
Ministry of Education Tier 1 FRC Grant R-397-000-333-114 (DH)
RIE2020 AME Programmatic Fund, Singapore A20G8b0102 (DH)
NMRC NMRC/TA/0014/2020 (RS)
NMRC MOH-OFLCG18May-0003 and NMRC/CG/M005/2017_NCIS (RS)
Singapore Gastric Cancer Consortium
Micron Foundation
Author Contributions
Conceptualization: AB, DH, RS
Methodology: AB, DH, CBT, BKJT, XT, RS
Investigation: AB, ATLT, LWJT, S-BT, DH, HLT, WPY, RS, S-BT, KSK
Visualization: AB, KSK, ATLT
Supervision: AB, RS, DH
Writing—original draft: AB, ATLT, LWJT, KSK, S-BT
Writing—review & editing: AB, ATLT, LWJT, KSK, S-BT, CBT, BKJT, XT, RS, DH, HLT, WPY
Competing Interests
DH reports equity in KYAN Therapeutics. RS reports support from Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, Eli Lilly, Roche, AstraZeneca, DKSH, MSD, Paxman Coolers, Natera, Astellas, GSK, Ipsen, Tavotek, Pierre-Fabre, Beigene, CytoMed, GSK, Daiichi-Sankyo outside the submitted work. CEC reports consulting/advisory roles for GuardantHealth AMEA, Roche Genentech, AstraZeneca, Merck and honoraria from AstraZeneca, Roche Genentech, PierreFabre, Merck, Amgen. WPY reports support from Abbvie/Genentech, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, MSD Oncology, Novartis and Taiho Pharmaceutical. AB, ATLT, LWJT, KSK, S-BT and DH are coinventors of previously filed pending patent(s) on artificial intelligence–based therapy development. The other authors declare no competing interests.
Data and Materials Availability
All data are available in the main text and the supplementary materials. The data sharing plan at clinicaltrials.gov has changed after the trial registration to include sharing of anonymized, individual patient data.